Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Specific antibody fragments for the human carcinoembryonic antigen (cea)

An antibody fragment and specific technology, applied in the field of immunology, can solve the problems of no development, abnormal biodistribution, low affinity of immobilized antigen, etc., and achieve the effect of good tissue penetration

Inactive Publication Date: 2005-08-03
CENT DE ING GENETICA & BIOTECNOLOGIA
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

scFv was produced in E. coli and demonstrated recognition of CEA in ELISA and cytochemical studies, but with a 200-fold lower affinity for the immobilized antigen than Fab obtained by natural methods (Pérez L et al., Applied Biochem Biotechnol, 24:79-82, 1996)
This same scFv fragment was cloned, expressed, and generated in Pichia pastoris (Freyre FM et al., J Biotechnol, 76(2-3):157-163, 2000), but without any improvement in affinity for human CEA , and studies using radiolabeled fragments in experimental animals indicated abnormal biodistribution (Pimentel GJ et al., Nucl MedCommun, 22: 1089-1094, 2001), so its further development was not pursued

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Specific antibody fragments for the human carcinoembryonic antigen (cea)
  • Specific antibody fragments for the human carcinoembryonic antigen (cea)
  • Specific antibody fragments for the human carcinoembryonic antigen (cea)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] Specific polypeptide molecules formed by one or more antigen-binding sites from a mouse Mab specific for human CEA are obtained by the present invention. Depending on how the polypeptide molecule is constructed, antigen binding sites are assembled into monovalent, bivalent, and other forms of antibody fragments.

[0027] A polypeptide molecule in the form of a monovalent scFv fragment specific to human CEA exhibits an affinity constant for the antigen of (5.0±0.4)×10 9 Lmol -1 , which comprises VH and VL domains connected in this order by a joint segment (linker) of 14 amino acids, the amino acid sequence of which is shown in SEQ ID NO16.

[0028] The polypeptide molecule in the form of a bivalent scFv fragment (dibody) specific to human CEA exhibits an affinity constant for the antigen of (2.8±0.3)×10 10 Lmol -1 , which comprises pairs of two identical molecules, each formed by VH and VL domains connected in this order by a joint segment (linker) of 5 amino acids, t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention relates to mono- and bivalent (diabody) single-chain Fv-type (scFv) antibody fragments which are obtained using recombinant DNA techniques from the carcinoembryonic anti-antigen (CEA) monoclonal antibody (McA) CB / ior-CEA.1. The aforementioned McA has a high affinity for the CEA and is used in the diagnosis and monitoring of colorectal tumours in humans. As with the original McA, diabody and monovalent scFv fragments exhibit high affinities for the human CEA and recognise an epitope that is dependent on carbohydrate conservation. The diabody and monovalent scFv fragments have affinity constants for the CEA of (5.0 + / - 0.4) x 10<9> L mol<-1> and (2.8 + / - 0.3) x 10<10> L mol<-1> respectively. The two aforementioned fragments do not display cross-reactivity with normal human tissues and cells, except for the normal colonic mucosa where the CEA is occasionally present. Said fragments can be produced through expression in recombinant micro-organisms from the cloning of nucleic acid sequences that code for variable regions obtained from the hybridoma that is produced by the CB / ior-CEA.1 McA. As with the original McA, the diabody and the monovalent scFv have a capacity for the in vivo identification in rats of human CEA-producing cells which grow forming tumours. The monovalent scFv and diabody do not posses Fc domains and the molecular sizes of said monovalent scFv and diabody are 5 and 2.5 times, respectively, less than the rat McA. As a result, the aforementioned monovalent scFv and diabody can better penetrate tissues in vivo and are less immunogenic in humans.

Description

technical field [0001] The present invention relates to the branch of immunology and, in particular, to monovalent and bivalent (dimeric) forms of single-chain Fv-type antibody fragments obtained by recombinant DNA techniques from mouse monoclonal antibodies with demonstrated clinical efficacy, and is specific to human carcinoembryonic antigen. Background of the invention [0002] Carcinoembryonic antigen (CEA) is a 180 kDa glycoprotein that is preferentially secreted by human gastrointestinal tumors and other cancer cells, however it can also be detected in some non-malignant tissues like colonic mucosa. Its physiological role has not been fully elucidated, so far it is considered to be related to the cell adhesion process in some aspects (Gold P, Freedman SO, Journal of Experimental Medicine, 122: 467, 1965; Zimmermann W et al., PNAS USA, 84: 2960 -2964, 1987; Paxton RJ et al., PNAS USA, 84:920-924, 1987; BeaucheminN et al., Molec Celluar Biol, 7:3...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/39A61K47/48C07K14/22C07K16/30
CPCC07K14/22A61K47/48569C07K2317/622C07K2317/626C07K16/3007A61K2039/505A61K39/00A61P35/00C07K16/30A61K51/10A61K47/6851
Inventor J·V·加维朗多考利M·阿亚拉艾维拉F·D·L·M·弗里尔阿美达B·E·阿瑟维多卡斯特罗H·贝尔卡希亚L·T·罗克纳瓦罗L·J·冈萨雷斯洛佩斯J·A·克里玛塔艾尔维利斯R·芒特希诺塞古伊
Owner CENT DE ING GENETICA & BIOTECNOLOGIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com